Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2016年 / 16卷 / 07期
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS COMPARED TO WARFARIN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION
    Gagliardi, Ilaria
    Bruni, Teresa
    Rauseo, Elisa
    Paravati, Vincenzo
    Barilla, Francesco
    Torromeo, Concetta
    Pannarale, Giuseppe
    Greco, Cesare
    Schiariti, Michele
    Gaudio, Carlo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 761 - 761
  • [22] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Dhamane, Amol D.
    Ferri, Mauricio
    Keshishian, Allison
    Russ, Cristina
    Atreja, Nipun
    Gutierrez, Cynthia
    Emir, Birol
    Yuce, Huseyin
    Di Fusco, Manuela
    ADVANCES IN THERAPY, 2023, 40 (03) : 887 - 902
  • [23] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Amol D. Dhamane
    Mauricio Ferri
    Allison Keshishian
    Cristina Russ
    Nipun Atreja
    Cynthia Gutierrez
    Birol Emir
    Huseyin Yuce
    Manuela Di Fusco
    Advances in Therapy, 2023, 40 : 887 - 902
  • [24] Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients
    Capodanno, Davide
    Capranzano, Piera
    Giacchi, Giuseppe
    Calvi, Valeria
    Tamburino, Corrado
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (04) : 1237 - 1241
  • [25] New anticoagulants in patients with non-valvular atrial fibrillation
    Zellerhoff, S.
    Lewalter, T.
    Eckardt, L.
    Treszl, A.
    Wegscheider, K.
    Breithardt, G.
    NERVENHEILKUNDE, 2012, 31 (11) : 813 - 820
  • [26] Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients Reply
    Balci, Kevser Gulcihan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (05):
  • [27] Comparative Outcomes of Direct Oral Anticoagulants versus Warfarin in Morbidly Obese Patients With Non-valvular Atrial Fibrillation
    Barakat, Amr F.
    Jain, Sandeep
    Masri, Ahmad
    Senussi, Mourad
    Wang, Yisi
    Bhonsale, Aditya
    Saba, Samir
    Mulukutla, Suresh R.
    CIRCULATION, 2019, 140
  • [28] Barriers to using warfarin in non-valvular atrial fibrillation
    Gattellari, M
    Zwar, NA
    Worthington, JM
    Middleton, S
    BRITISH MEDICAL JOURNAL, 2006, 332 (7536): : 303 - 304
  • [29] ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON)
    Derosa, Giuseppe
    Rizzo, Manfredi
    Brunetti, Natale Daniele
    Raddino, Riccardo
    Gavazzoni, Mara
    Pasini, Gianfranco
    Gaudio, Giovanni
    Maggi, Antonio
    D'Angelo, Angela
    De Gennaro, Luisa
    Maffioli, Pamela
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (08)
  • [30] Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation
    Destephan, C.
    Waller, A. H.
    Patel, R. J.
    Dhruvakumar, S.
    Mazza, V.
    Gerula, C.
    Maher, J.
    Kaluski, E.
    MINERVA CARDIOANGIOLOGICA, 2012, 60 (04): : 425 - 431